All Releases
Ligand Initiates Clinical Trial with the Selective Androgen Receptor Modulator LGD-4033, a Potential Treatment of Muscle and Bone Disorders
Jun 17, 2009
|
CORRECTING and REPLACING Ligand Pharmaceuticals Announces First Quarter Results
May 11, 2009
|
Ligand Pharmaceuticals Announces First Quarter Results
May 6, 2009
|
Ligand to Hold First Quarter Results Conference Call on May 6
Apr 28, 2009
|
Ligand Announces Approval in Europe of CONBRIZA(TM)for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Apr 27, 2009
|
Ligand and GlaxoSmithKline Collaboration Identifies New Lead Compound
Mar 30, 2009
|
FABLYN(R) Approved in Europe for the Treatment of Osteoporosis
Mar 24, 2009
|
Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results
Feb 12, 2009
|
Ligand Pharmaceuticals and The Rockefeller University Enter Settlement Agreement and Mutual Release
Feb 12, 2009
|
Ligand Earns $1 Million Milestone Payment on Progress of Drug Candidate for Alzheimer's Disease
Feb 9, 2009
|
Ligand Enters into Screening Agreement with Trevena
Feb 6, 2009
|
Ligand to Present at BIO CEO and Investor Conference on February 9
Feb 3, 2009
|
Ligand Announces Phase IIb Results With DARA
Feb 2, 2009
|
Ligand to Hold Fourth Quarter Results Conference Call on February 12
Jan 29, 2009
|
Ligand Announces Board of Directors Changes
Jan 21, 2009
|
Ligand Completes Pharmacopeia Acquisition
Dec 23, 2008
|
Ligand Enters into Exclusive License Agreement with GlaxoSmithKline to License Rights to LGD-4665 and other Ligand Thrombopoietin (TPO) Molecules
Dec 18, 2008
|
Ligand Presents Positive LGD-4665 Clinical Trial Results at the American Society of Hematology Annual Meeting
Dec 8, 2008
|
Ligand Collaborator GlaxoSmithKline Receives FDA Approval for PROMACTA®
Nov 20, 2008
|
Ligand Pharmaceuticals Announces Third Quarter Results
Nov 6, 2008
|
|
|
